IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0157635.html
   My bibliography  Save this article

Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder

Author

Listed:
  • Dusan Hirjak
  • Achim Hochlehnert
  • Philipp Arthur Thomann
  • Katharina Maria Kubera
  • Knut Schnell

Abstract

Background: Schizophrenia spectrum disorders result in enormous individual suffering and financial burden on patients and on society. In Germany, there are about 1,000,000 individuals suffering from schizophrenia (SZ) or schizoaffective disorder (SAD), a combination of psychotic and affective symptoms. Given the heterogeneous nature of these syndromes, one may assume that there is a difference in treatment costs among patients with paranoid SZ and SAD. However, the current the national system of cost accounting in psychiatry and psychosomatics in Germany assesses all schizophrenia spectrum disorders within one category. Methods: The study comprised a retrospective audit of data from 118 patients diagnosed with paranoid SZ (F20.0) and 71 patients with SAD (F25). We used the mean total costs as well as partial cost, i.e., mean costs for medication products, mean personal costs and mean infrastructure costs from each patient for the statistical analysis. We tested for differences in the four variables between SZ and SAD patients using ANCOVA and confirmed the results with bootstrapping. Results: SAD patients had a longer duration of stay than patients with SZ (p = .02). Mean total costs were significantly higher for SAD patients (p = .023). Further, we found a significant difference in mean personnel costs (p = .02) between patients with SZ and SAD. However, we found no significant differences in mean pharmaceutical costs (p = .12) but a marginal difference of mean infrastructure costs (p = .05) between SZ and SAD. We found neither a common decrease of costs over time nor a differential decrease in SZ and SAD. Conclusion: We found evidence for a difference of case related costs of inpatient treatments for paranoid SZ and SAD. The differences in mean total costs seem to be primarily related to the mean personnel costs in patients with paranoid SZ and SAD rather than mean pharmaceutical costs, possibly due to higher personnel effort and infrastructure.

Suggested Citation

  • Dusan Hirjak & Achim Hochlehnert & Philipp Arthur Thomann & Katharina Maria Kubera & Knut Schnell, 2016. "Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder," PLOS ONE, Public Library of Science, vol. 11(7), pages 1-10, July.
  • Handle: RePEc:plo:pone00:0157635
    DOI: 10.1371/journal.pone.0157635
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0157635
    Download Restriction: no

    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0157635&type=printable
    Download Restriction: no

    File URL: https://libkey.io/10.1371/journal.pone.0157635?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Alex Dregan & Ann McNeill & Fiona Gaughran & Peter B Jones & Anna Bazley & Sean Cross & Kate Lillywhite & David Armstrong & Shubulade Smith & David P J Osborn & Robert Stewart & Til Wykes & Matthew Ho, 2020. "Potential gains in life expectancy from reducing amenable mortality among people diagnosed with serious mental illness in the United Kingdom," PLOS ONE, Public Library of Science, vol. 15(3), pages 1-16, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0157635. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.